Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | ALT-803 + CIML-NK cells |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ALT-803 | N-803|N803|Nogapendekin alfa|ALT803 | ALT-803 (Nogapendekin alfa) is a fusion protein consisting a mutant IL-15 and a soluble IL-15Ra Fc, which activates and converts memory CD8+ T cells to effector immune cells with antitumor activity (PMID: 24404427, PMID: 31338557). | ||
CIML-NK cells | CIML-NK cells are allogeneic cytokine-induced memory-like natural killer (CIML-NK) cells, which potentially enhance cytotoxic anti-tumor immune response (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04290546 | Phase I | ALT-803 + CIML-NK cells + Ipilimumab ALT-803 + CIML-NK cells | CIML NK Cell in Head & Neck Cancer | Recruiting | USA | 0 |